Targeting Nuclear Hormone Receptors : PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis

Abstract EN

In recent years, peroxisome proliferator-activated receptors (PPARs) have received growing interest due to the broad spectrum of their biological activities.

PPARα, an isoform of PPAR, plays an important role in lipid homeostasis and inflammation, which makes it a potential target for the treatment of chronic inflammatory disorders, including RA.

This paper reviews studies on the properties of PPARα agonists which may be pertinent to the treatment of RA.

These properties include effects on lipid metabolism, inflammation, and angiogenesis, as well as interference with glucocorticoid effects, and a potential role in gender dimorphism of autoimmune disorders.

However, current clinical experience with this class of drugs in RA is limited.

New studies are needed to elucidate whether PPARα agonism may be an effective treatment strategy for RA patients.